In this study we sought out to investigate whether AMG 330 could simultaneously confer two hits by redirecting T-cells against both CD33+ AML-blasts and CD33+ MDSCs thereby further enhancing anti-leukemic immune activity. The gene discussed is CD33; the disease is acute myeloid leukemia.